Price Range (₹)
Issue Size (₹ in Cr.)
Minimum Quantity
Bidding Period
| Shareholder | |
| Retail Individual Investor | |
| Non-Institutional Investor | |
| Qualified Institutional Buyers | |
| Employee | |
| Overall |
- A pharmaceutical contract development and manufacturing organization (“CDMO”) offering a comprehensive range of pharmaceutical products and services in India and overseas
- During the FY24, they had a market share of 30.2% of the Indian domestic CDMO market by value, which increased from 26.7% during the FY21
- Since their inception, they have manufactured 4,146 commercialised formulations across over 60 dosage forms
Largest CDMO serving the Indian pharmaceutical industry
The largest India-focused CDMO in terms of revenue, production capacity and clients served during the FY23 (among CDMOs assessed by F&S). Along with its subsidiaries, as of March 31, 2024, they operate 12 manufacturing units with a cumulative formulations manufacturing capacity aggregating to 49.23 billion units annually, to produce a wide range of dosage forms (Source: F&S Report)
Diverse client base with longstanding CDMO relationships
As of March 31, 2024, their client base for CDMO business comprised 1,524 Indian and multinational pharmaceutical and wellness companies, increasing from 1,386 as of March 31, 2022. During the FY24, they manufactured formulations for 26 of the leading 30 pharmaceutical companies in terms of sales in India. Furthermore, they have benefitted from repeat orders in the past 5 years from 38 of their 50 largest clients in terms of revenue for CDMO business, as of March 31, 2024 (Source: F&S Report)
Large and rapidly growing R&D capabilities across their product portfolio
As of March 31, 2024, they operate four dedicated R&D units and engaged 406 R&D scientists across their businesses. Two of their R&D units are approved by the Department of Scientific and Industrial Research, Ministry of Science and Technology, Government of India. As of March 31, 2024, they have obtained 1,448 trademarks across various dosage forms and formulations. Further, as of March 31, 2024, they have procured 927 DCGI approvals and five patents (Source: F&S Report)
Any slowdown or shutdown in manufacturing and R & D operations could have an adverse effect on business
Business is dependent upon their ability to operate manufacturing units and R&D centers without disruption. Factors beyond their control, including disruption in electrical power or water resources, political instability, industrial accidents or machinery breakdowns, severe weather conditions, natural disasters, and outbreak of infectious diseases, could result in a slowdown or shutdown of their operations and adversely affect business. (Source: Company RHP)
They have incurred losses in the past and may incur losses in the future.
Their ability to operate profitably depends on a number of factors, some of which are beyond their control. While they recorded profits during the FY24 and FY23, they incurred losses aggregating to ₹2,508.74 million during the FY22.These losses were primarily due to accounting adjustments relating to fair value changes to financial instruments (put option liability) of ₹4,941.74 million during FY22 (Source: Company RHP)
- Resilient and sustainable long-term growth has been evident in the pharma segment : The pharmaceutical market is pivotal in advancing global healthcare, encompassing critical aspects such as research, development, manufacturing, and distribution of pharmaceutical products, including drugs, vaccines, and biotechnology-based therapies. Valued at USD 1,634.8 billion in 2023, the market is projected to reach USD 2,119.0 billion by 2027, with a CAGR of 6.7% from 2023 to 2027
- India is emerging as the preferred destination for pharma outsourcing: In the realm of pharmaceuticals, a notable shift has emerged where both Indian and International pharmaceutical firms are showing a growing inclination toward collaborating with Indian CDMOs. This preference is attributed to several compelling business factors: Cost Efficiency, Expert talent pool, Ease of doing business, Government policies supporting local pharma manufacturing,Government’s FDI policy for the pharma sector,Regulatory-compliant infrastructure,Scalability, customization, and flexibility,Access to technology, Diversity in formulation capability
For ICICI Bank linked A/c
For non ICICI Bank A/c
Go to the IPO section, select the IPO you want to apply from the list and click on ‘Apply’.
Fill in the quantity of the number of shares you want to buy. To apply at maximum price, check the cut-off price box and amount is auto calculated. If you want to apply at some other price within the price band, then you can enter the price manually by clicking on “Add bid” option.
Click on proceed to confirm the order. You can view the placed order under “order book”.
Choose the IPO you want to apply from the list. Click on Apply.
Fill in the quantity of shares. To apply at maximum price, check the cut-off price box and amount is auto calculated. If you want to apply at some other price within the price band, then you can enter the price manually by clicking on “Add bid” option.
Check the A/C, UPI details and click on proceed. You will get an UPI link by which payment can be made.
The lot size is 22 shares and minimum investment required is Rs.14,938 for Akums
Akums Drugs IPO is mainboard IPO of issue size up to Rs.1856.74 Crores
Akums Drugs IPO issue dates are from 30th July – 01st Aug, 2024.
The allotment date is 2nd Aug, 2024 and listing date is 6th Aug, 2024 for Akums Drugs IPO.
Head to IPO section on ICICI Direct website and select Akums Drugs IPO. Enter and submit bid details and then click on proceed to apply once details are verified. It’s that simple!!
The price band of Akums Drugs IPO is Rs.646 – Rs.679.
The book runners for the Akums Drugs IPO are ICICI Securities Ltd, Axis Bank Ltd, Citigroup Global Markets India Pvt Ltd, Ambit Pvt Ltd
The objective of Akums Drugs IPO is for
No, you cannot submit for more than one application with a single PAN in Akums Drugs IPO
Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
